Kyle Umipig – Longevity.Technology –
Engitix is betting that fixing the body’s damaged tissue environment could unlock better cancer care and a longer healthspan.
London-based Engitix has secured a $25 million Series A extension from existing investor Netherton Investments, investing on behalf of Mike Platt, co-founder and managing director of BlueCrest Capital Management.
